{"id":60831,"date":"2026-05-06T08:08:43","date_gmt":"2026-05-06T08:08:43","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/60831\/"},"modified":"2026-05-06T08:08:43","modified_gmt":"2026-05-06T08:08:43","slug":"novartis-to-close-site-in-germany-and-cut-220-jobs","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/60831\/","title":{"rendered":"Novartis to close site in Germany and cut 220 jobs"},"content":{"rendered":"

\"Novartis<\/p>\n

Novartis says the production site in \u200bWehr, Germany, which manufactures tablets and capsules, is no longer competitive. <\/p>\n

Keystone-SDA <\/p>\n

Swiss drugmaker Novartis says it will cut around 220 jobs in Germany as part \u200bof the planned \u200bclosure of a production site in Wehr \u2060by the end of \u200b2028.\n<\/p>\n

Listen to the article <\/p>\n

Listening the article <\/p>\n

Toggle language selector <\/p>\n

English (US) <\/p>\n

English (British) <\/p>\n

Generated with artificial intelligence. <\/p>\n

This content was published on <\/p>\n

May 6, 2026 – 09:41\n<\/p>\n

+Get the most important news from Switzerland in your inbox<\/a><\/p>\n

Novartis says the production site in \u200bWehr, Germany, which manufactures tablets and capsules, is no longer competitive. <\/p>\n

\u201cWe are aware of the uncertainty that this announcement brings to our colleagues in Wehr,\u201d Steffen Lang, head of production at Novartis, said in a statement. <\/p>\n

The group promises transparent and respectful cooperation with employees and the municipal authorities concerned.<\/p>\n

\n More<\/p>\n

\"Novartis<\/p>\n

More <\/p>\n

New treatments\n <\/p>\n

Swiss pharma firm Novartis plans seventh US plant <\/p>\n

\n

This content was published on <\/p>\n

Apr 30, 2026 <\/p>\n

Novartis is expanding its production capacity in the United States, with the announcement of a new site in Morrisville, North Carolina. This plant will bring to seven the number of new sites planned as part of its $23 billion investment plan. <\/p>\n

<\/p>\n

Read more: Swiss pharma firm Novartis plans seventh US plant
\n <\/a><\/p>\n

Novartis assures that the closure will not jeopardise patient supplies and reaffirms its commitment to Germany, where the company employs 2,600 staff at six sites.<\/p>\n

Meanwhile, Novartis has announced that it will invest \u20ac35 million (CHF32 million) in a new cancer therapy plant in Halle, Saxony-Anhalt, which is expected to be operational in 2027.<\/p>\n

\n More<\/p>\n

\"Roche<\/p>\n

More <\/p>\n

Healthcare innovation\n <\/p>\n

US trade deal forces reckoning for Swiss pharma powerhouse <\/p>\n

\n

This content was published on <\/p>\n

Nov 18, 2025 <\/p>\n

Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry\u2019s future in Switzerland. <\/p>\n

<\/p>\n

Read more: US trade deal forces reckoning for Swiss pharma powerhouse
\n <\/a><\/p>\n

Adapted from French by AI\/sb<\/p>\n

How we work\u00a0 <\/p>\n

We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.\u00a0\u00a0<\/p>\n

Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.<\/p>\n

If you have any questions about how we work, write to us at english@swissinfo.ch<\/a><\/p>\n

Articles in this story <\/p>\n","protected":false},"excerpt":{"rendered":"Novartis says the production site in \u200bWehr, Germany, which manufactures tablets and capsules, is no longer competitive. Keystone-SDA…\n","protected":false},"author":2,"featured_media":60832,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[101,300,629,5321,33588,100,304,103,17,21313],"class_list":{"0":"post-60831","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-switzerland","8":"tag-article","9":"tag-beat-pharma-supply-chains","10":"tag-beat-workplace","11":"tag-employment","12":"tag-job-layoffs","13":"tag-latest-news","14":"tag-pharmaceutical","15":"tag-production-type-deepl-autotranslation","16":"tag-switzerland","17":"tag-user-need-update-me"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116526612650325396","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/60831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=60831"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/60831\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/60832"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=60831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=60831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=60831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}